| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0511 | Name | FR0348383 | Aliases | N/A | |
| Species | Homo sapiens | Chromosome | N/A | Start site | N/A | |
| End site | N/A | Chain | N/A | Exon NO. | N/A | |
| Assembly | N/A | Class | N/A | NCBI accession | N/A | |
| Ensembl | N/A | Sequence | N/A | |||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| prostate cancer | qRT-PCR | Post-digital rectal examination (DRE) first-catch urine specimens prior to prostate biopsies | up-regulated | expression | FR0348383 transcript in post-DRE urine may be a novel biomarker for detection of PCa with great diagnostic value, especially in the grey zone cohort. | 25597901 | |||
| prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer | ||